CW July 2005
Volume 14Issue Number 7 July 2005 ISSN 10593802 Erlotinib Plus Gemcitabine Improves Pancreatic Cancer SurvivalAdding the targeted therapy erlotinib (Tarceva) to the chemotherapy gemcitabine significantly improves survival in advanced pancreatic cancer patients. This is the first clinical trial to show a survival benefit in advanced pancreatic cancer.
Go to Previous Page Go to Next Page Source & Additional Reading M. J. Moore, 41st Annual Meeting of the American Society of Clinical Oncology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
